[Evaluation of the use of a simulation software in the learning of cardiopulmonary auscultation in undergraduate medical students]. / Evaluation de l'utilisation d'un logiciel de simulation dans l'apprentissage de l'auscultation cardio-pulmonaire chez les étudiants en premier cycle d'études médicales.

INTRODUCTION: Medsounds™ software allows to create an auscultation learning platform, by providing real pre-recorded cardiopulmonary sounds on virtual chests. The study aimed at comparing the skills in cardiopulmonary auscultation between students who benefited from this platform and students who did not have access to it. METHODS: A controlled trial was conducted with 2nd year medical students randomised into three groups. Groups A, B and C received 10 h of cardiopulmonary clinical training. In addition, group B benefited from an online access to the educative platform, and group C had a demonstration of the platform during their clinical training, then an online access. The main outcome was a 3-point multiple-choice questionnaire based on 2 original case vignettes about the description of cardiopulmonary sounds. The secondary outcome was the faculty exam on high-fidelity cardiopulmonary simulator. RESULTS: Groups A and B included 127 students, and group C 117. Students in group C had a significantly higher score than those in group A (1.72/3 versus 1.48/3; p = 0.02), without difference between the groups B and C. Students who actually had a demonstration of the platform and used it at home had a higher score than those who did not use it (1.87 versus 1.51; p = 0.01). Students who had a demonstration of the platform before using it performed a better pulmonary examination on high-fidelity simulators. CONCLUSION: The supervised use of an online auscultation simulation software in addition to the traditional clinical training seems to improve the auscultation performances of undergraduated medical students.

Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.

In heart transplantation, there is a lack of robust evidence of the specific causes of late allograft failure. We hypothesized that a substantial fraction of failing heart allografts may be associated with antibody-mediated injury and immune-mediated coronary arteriosclerosis. We included all patients undergoing a retransplantation for late terminal heart allograft failure in three referral centers. We performed an integrative strategy of heart allograft phenotyping by assessing the heart vascular tree including histopathology and immunohistochemistry together with circulating donor-specific antibodies. The main analysis included 40 explanted heart allografts patients and 402 endomyocardial biopsies performed before allograft loss. Overall, antibody-mediated rejection was observed in 19 (47.5%) failing heart allografts including 16 patients (40%) in whom unrecognized previous episodes of subclinical antibody-mediated rejection occurred 4.5 ± 3.5 years before allograft loss. Explanted allografts with evidence of antibody-mediated rejection demonstrated higher endothelitis and microvascular inflammation scores (0.89 ± 0.26 and 2.25 ± 0.28, respectively) compared with explanted allografts without antibody-mediated rejection (0.42 ± 0.11 and 0.36 ± 0.09, p = 0.046 and p < 0.0001, respectively). Antibody-mediated injury was observed in 62.1% of failing allografts with pure coronary arteriosclerosis and mixed (arteriosclerosis and atherosclerosis) pattern, while it was not observed in patients with pure coronary atherosclerosis (p = 0.0076). We demonstrate that antibody-mediated rejection is operating in a substantial fraction of failing heart allografts and is associated with severe coronary arteriosclerosis. Unrecognized subclinical antibody-mediated rejection episodes may be observed years before allograft failure.

Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies.

Anti-HLA donor-specific antibodies (DSAs) cause acute and chronic antibody-mediated rejection (AMR). However, the clinical relevance of anti-HLA-C antibodies remains unclear. We evaluated the clinical relevance of the presence of anti-HLA-C DSA at day 0 in renal transplant recipients. In this retrospective, case-controlled study, 608 patients who underwent kidney transplantation between August 2008 and March 2012 were screened for the presence of isolated anti-HLA-C DSA at day 0. A total of 22 renal transplant recipients were selected and followed for a period of 1 year. AMR was classified according to the Banff classification. The 22 patients were compared with 88 immunized patients. Acute AMR was diagnosed in six patients (27.3%). The median level of DSA at day 0 was 1179 (530-17,941). The mean fluorescence intensity in the anti-C group was 4966 (978-17,941) in the AMR group and 981 (530-8012) in the group of patients without AMR. Acute AMR was diagnosed less frequently in the 88 immunized individuals (9.1%) than in the DSA anti-C group (p = 0.033). The level of DSA at day 0 was predictive for AMR (p = 0.017). Patients with a high level of pretransplant anti-HLA-C DSAs are likely to develop acute AMR during the first year after transplantation.

[Contribution of 64-slice cardiac tomodensitometry for non-invasive diagnosis of acute myocarditis]. / Apport de la tomodensitométrie cardiaque-64 coupes au diagnostic non invasif de la myocardite aiguë

BACKGROUND: The association of acute chest pain, elevation of the cardiac enzymes and biological markers of inflammation suggests the diagnosis of myocarditis. The aim of the present study is to evaluate the diagnostic value of the multidetectors cardiac tomodensitometry (MDCT) for the confirmation of this diagnosis. PATIENTS AND METHODS: From October 2005 to April 2011, 39 patients aged 15.4 to 75.7years (mean 43.3±15.1) underwent a MDCT for suspected acute myocarditis (chest pain, elevation of troponin I, systemic inflammation). The electrocardiogram highlighted repolarization disorders in 27 (69%) patients (negative T waves, elevation of ST segment). The MDCT consisted in a first acquisition phase (imaging of coronary arteries) followed 7minutes later by a late acquisition, with thicker slices (imaging of the myocardium). When the MDCT was performed after a coronary angiography, only the late acquisition was performed. Sixteen patients then underwent a cardiac MRI. RESULTS: No significant coronary stenoses were found in all patients. The MDCT showed homogeneous myocardial enhancement on the early acquisition. A subepicardial late enhancement was found in 30 (76.9%) patients. The subepicardial enhancement was mainly found in the lateral myocardium. In patients who underwent cardiac MRI and MDCT (n=16), there was a good correlation between the enhanced segments. MDCT found differential diagnosis in 11 patients (myocardial infarction, Tako-Tsubo). CONCLUSION: The ECG-gated MDCT is a non-invasive and reliable diagnostic tool in patient with suspected myocarditis. It allows at the same time to rule out a significant coronary disease, when no coronary angiography was performed, and to show subepicardial enhancement confirming the diagnosis of myocarditis. While cardiac MRI remains the gold standard, MDCT could prove useful when there is no access to or contraindication for an MRI, studying both the coronary arteries and the myocardium.